University of Pittsburgh had begun immunization experiments in monkeys using dead polio virus. Soon, however, Salk began to test inoculations in paralyzed polio patients and by 1953 human trials among the general population were initiated. By the spring of the following year, the largest controlled field trials in medical history were underway, and by 1955 the vaccine developed by Salk and his researchers was declared effective. By 1962, Salk's vaccine had reduced the incidence of polio in the United States by 95 percent. The breakthroughs in immunology and vaccine development at Pitt by Salk and his team are considered one of the most
Jonas Salk units set on a bluff overlooking the Pacific, Dr. Salk holds the titles of founding director and resident fellow. His own laboratory group is concerned with the immunologic aspects of cancer and the mechanisms of autoimmune disease, such as multiple sclerosis, in which the immune system attacks the body's own tissues. In an interview about his future hopes at the institute, he said, "In the end, what may have more significance is my creation of the institute and what will come out of it, because of its example as a place for excellence, a creative environment for creative minds." Francis